Eric S. Lightcap

2.1k total citations
33 papers, 1.3k citations indexed

About

Eric S. Lightcap is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Eric S. Lightcap has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 11 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Eric S. Lightcap's work include Ubiquitin and proteasome pathways (13 papers), Cancer-related Molecular Pathways (5 papers) and Metabolism and Genetic Disorders (3 papers). Eric S. Lightcap is often cited by papers focused on Ubiquitin and proteasome pathways (13 papers), Cancer-related Molecular Pathways (5 papers) and Metabolism and Genetic Disorders (3 papers). Eric S. Lightcap collaborates with scholars based in United States, Japan and France. Eric S. Lightcap's co-authors include Vincent Chau, Julian Adams, Christine Pien, Peter J. Elliott, Teresa A. McCormack, Joan S. Brugge, Seth Sadis, Ronald K. Blackman, James Fleming and Christine Bulawa and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Eric S. Lightcap

31 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric S. Lightcap United States 15 1.1k 441 215 161 134 33 1.3k
Dominico Vigil United States 19 1.7k 1.5× 396 0.9× 295 1.4× 177 1.1× 94 0.7× 26 2.0k
X. Wei Meng United States 21 901 0.8× 335 0.8× 134 0.6× 162 1.0× 103 0.8× 31 1.4k
Xiangao Sun United States 12 1.3k 1.1× 497 1.1× 133 0.6× 224 1.4× 168 1.3× 13 1.6k
Tiziana Bruno Italy 22 1.4k 1.2× 674 1.5× 144 0.7× 337 2.1× 75 0.6× 52 1.7k
Marc L. Hyer United States 19 909 0.8× 438 1.0× 370 1.7× 135 0.8× 56 0.4× 38 1.3k
Dale Grabowski United States 22 1.1k 1.0× 650 1.5× 128 0.6× 106 0.7× 124 0.9× 67 1.4k
Teresa A. McCormack Ireland 10 742 0.7× 293 0.7× 118 0.5× 160 1.0× 175 1.3× 10 1.0k
Richard I. Feldman United States 11 1.3k 1.2× 524 1.2× 347 1.6× 209 1.3× 62 0.5× 15 1.8k
Richard A. Norman United Kingdom 18 1.0k 0.9× 269 0.6× 91 0.4× 145 0.9× 66 0.5× 26 1.5k
Vanessa C. Gray‐Schopfer United Kingdom 7 1.3k 1.2× 733 1.7× 293 1.4× 195 1.2× 87 0.6× 8 1.9k

Countries citing papers authored by Eric S. Lightcap

Since Specialization
Citations

This map shows the geographic impact of Eric S. Lightcap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric S. Lightcap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric S. Lightcap more than expected).

Fields of papers citing papers by Eric S. Lightcap

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric S. Lightcap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric S. Lightcap. The network helps show where Eric S. Lightcap may publish in the future.

Co-authorship network of co-authors of Eric S. Lightcap

This figure shows the co-authorship network connecting the top 25 collaborators of Eric S. Lightcap. A scholar is included among the top collaborators of Eric S. Lightcap based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric S. Lightcap. Eric S. Lightcap is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tameire, Feven, Crissy Dudgeon, Kathryn Bieging-Rolett, et al.. (2025). In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation. Molecular Cancer Therapeutics. 25(1). 71–83.
2.
McKay, Rana R., Pedro C. Barata, Moshe Chaim Ornstein, et al.. (2024). 5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605. The Oncologist. 29(Supplement_1). S13–S13. 1 indexed citations
3.
Dudek, Arkadiusz Z., Joyce O’Shaughnessy, Sarina A. Piha‐Paul, et al.. (2024). A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15118–e15118. 10 indexed citations
4.
Stokes, Michael E., Verónica Calvo, Sho Fujisawa, et al.. (2023). PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors. Clinical Cancer Research. 29(23). 4870–4882. 16 indexed citations
5.
Morita, Tomoko, Jie Yu, Yukie Kashima, et al.. (2023). CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade. Nature Communications. 14(1). 7490–7490. 12 indexed citations
6.
Bieging-Rolett, Kathryn, Crissy Dudgeon, Michael E. Stokes, et al.. (2023). Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML. Blood. 142(Supplement 1). 2943–2943. 3 indexed citations
7.
Liu, Hong, Suryasarathi Dasgupta, Yu Fu, et al.. (2019). Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD. BMC Immunology. 20(1). 42–42. 48 indexed citations
8.
Lightcap, Eric S., et al.. (2015). Acoustic Liquid Handling for Rapid siRNA Transfection Optimization. SLAS DISCOVERY. 20(8). 957–964. 3 indexed citations
9.
Garcia, Khristofer, Jonathan L. Blank, David C. Bouck, et al.. (2014). Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways. Molecular Cancer Therapeutics. 13(6). 1625–1635. 45 indexed citations
10.
Blank, Jonathan L., Katherine Cosmopoulos, David C. Bouck, et al.. (2012). Novel DNA Damage Checkpoints Mediating Cell Death Induced by the NEDD8-Activating Enzyme Inhibitor MLN4924. Cancer Research. 73(1). 225–234. 85 indexed citations
11.
Sappal, Darshan S., Neil Bence, Paul Fleming, et al.. (2011). Cellular and biochemical characterization of an inhibitor of the Ubiquitin Activating Enzyme (UAE). 2. 1 indexed citations
12.
Robison, Keith, Eric S. Lightcap, Vlado Dančík, et al.. (2005). Edge‐count probabilities for the identification of local protein communities and their organization. Proteins Structure Function and Bioinformatics. 62(3). 800–818. 24 indexed citations
13.
Nandi, Dhirendra L., et al.. (2003). Purification and inactivation of 3-hydroxyanthranilic acid 3,4-dioxygenase from beef liver. The International Journal of Biochemistry & Cell Biology. 35(7). 1085–1097. 7 indexed citations
14.
Elliott, Peter J., Teresa A. Soucy, Christine Pien, Julian Adams, & Eric S. Lightcap. (2003). Assays for Proteasome Inhibition. Humana Press eBooks. 85. 163–172. 17 indexed citations
15.
Fleming, James, et al.. (2002). Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. Proceedings of the National Academy of Sciences. 99(3). 1461–1466. 159 indexed citations
16.
Lightcap, Eric S., Teresa A. McCormack, Christine Pien, et al.. (2000). Proteasome Inhibition Measurements: Clinical Application. Clinical Chemistry. 46(5). 673–683. 243 indexed citations
17.
Podust, Vladimir N., James E. Brownell, Tatiana Gladysheva, et al.. (2000). A Nedd8 conjugation pathway is essential for proteolytic targeting of p27 Kip1 by ubiquitination. Proceedings of the National Academy of Sciences. 97(9). 4579–4584. 215 indexed citations
18.
Lightcap, Eric S. & Richard B. Silverman. (1996). Slow-Binding Inhibition of γ-Aminobutyric Acid Aminotransferase by Hydrazine Analogues,. Journal of Medicinal Chemistry. 39(3). 686–694. 23 indexed citations
19.
Lightcap, Eric S., et al.. (1995). Time-dependent inhibition of γ-aminobutyric acid aminotransferase, by 3-hydroxybenzylhydrazine. Bioorganic & Medicinal Chemistry. 3(5). 579–585. 4 indexed citations
20.
Lightcap, Eric S., Christopher J. Halkides, & Perry A. Frey. (1991). Interactions of metal ions with .mu.-monothiopyrophosphate. Biochemistry. 30(42). 10307–10313. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dominico Vigil Breakdown of academic impact, for papers by X. Wei Meng Breakdown of academic impact, for papers by Xiangao Sun Breakdown of academic impact, for papers by Tiziana Bruno Breakdown of academic impact, for papers by Marc L. Hyer Breakdown of academic impact, for papers by Dale Grabowski Breakdown of academic impact, for papers by Teresa A. McCormack Breakdown of academic impact, for papers by Richard I. Feldman Breakdown of academic impact, for papers by Richard A. Norman Breakdown of academic impact, for papers by Vanessa C. Gray‐Schopfer
Rankless by CCL
2026